



INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				Complete if Known		
				Application Number	10/685,267	
				Filing Date	October 14, 2003	
Sheet	1	of	1	First Name Inventor	Ding, et al.	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	
		Number	Kind Code <sup>2</sup> (if known)			
A						
<b>FOREIGN PATENT DOCUMENTS</b>						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number	Kind Code <sup>4</sup> (if known)		
AJW	B1	WO99/21845	Agouron Pharmaceuticals Inc.			05/06/1999
	B2	WO00/75120	Agouron Pharmaceuticals Inc.			12/14/2000
	B3	WO97/16447	Mitotix Inc.			05/09/1997
	B4	WO99/43675	Hoechst Marion Roussel Inc.			09/02/1999
	B5	WO99/43676	Hoechst Marion Roussel Inc.			09/02/1999
	B6	WO98/33798	Warner Lambert Co.			08/06/1998
	B7	WO99/09030	Warner Lambert Co.			02/25/1999
	B8	WO00/39101	Astrazeneca Ltd.			07/06/2000
	B9	WO00/12485	Zeneca Ltd.			03/09/2000
	B10	WO99/24416	Bristol-Myers Squibb Co.			03/09/1999
	B11	WO99/21845	Agouron Pharmaceuticals Inc.			05/06/1999
	B12	WO 00/26202	Pharmacia & UpJohn S.P.A.			05/11/2000
	B13	WO 01/56567	Novo Nordisk A/S			08/09/2001
	B14	WO 01/60816	Amgen Inc.			08/23/2001
	B15	WO 01/79198	Agouron Pharmaceuticals, Inc.			12/25/2001
AJW	B16	WO 02/12250	Agouron Pharmaceuticals, Inc.			02/14/2002
<b>NON PATENT LITERATURE DOCUMENTS</b>						
AJW	C1	Senderowicz, A.M., et al. J. Nat'l. Cancer Inst. 2000 Vol. 92 pgs. 376-387				
	C2	Chong, Wesley, K. M., Presentation at Gordon Conference on Medicinal Chemistry, Colby Sawyer College, New London, NH "Novel ATP Site Inhibitors of the Cyclin Dependent Kinases", August 2, 1999 ( <b>Copy of Conference Handout Enclosed</b> )				
	C3	Fischer et al., Expert Opin. Investig. Drugs 12(6) pgs. 955-970 (2003)				
AJW	C4	Grant et al., Drug Resistance Vol. 6, pgs. 15-26 (2003)				
Examiner Signature		Date Considered	A. H. Dwyer 4/29/05			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

137761